Zoetis Inc (ZTS) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Total Cash From Operating Activities Chart for Zoetis Inc
Zoetis Inc (ZTS) operating cash flow for FY2025 was USD 2.9B, a -1.7% change from FY2024. Zoetis Inc's operating cash flow grew from USD 98.0M in 2009 to USD 2.9B in 2025 (2863.3% over 16 years). Operating cash flow compound annual growth rate: 5-year CAGR of 6.4%, 10-year CAGR of 15.9%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $30.49B
- Implied Share Price
- $73.79
- Enterprise Value
- $38.06B
- Revenue (TTM)
- $9.53B
- EBITDA
- $4.07B
- Profit Margin
- 27.69%
- Trailing P/E
- 12.04
- Forward P/E
- 11.90
- Price/Book (MRQ)
- 9.69
- Price/Sales (TTM)
- 3.20
- EV/EBITDA
- 9.47
- EV/Revenue
- 4.00
- Dividend Yield
- 2.72%
- Book Value
- $7.84
- Free Cash Flow (FY2025)
- $2.28B
- Free Cash Flow Yield
- 7.49%
Snapshot as of 16th August 2026 — not point-in-time controlled, may lag the live market by a few days.